Latest Healthcare News

Tissue Repair Limited reports steady progress in its Phase 3 clinical trials for TR987® despite patient recruitment hurdles, while TR Pro+® sales surge and new distribution deals pave the way for international growth.

Clarity Pharmaceuticals has bolstered its cash reserves to approximately $288 million following a $203 million institutional placement, while reporting significant clinical progress across multiple copper-based radiopharmaceutical trials targeting prostate cancer and neuroendocrine tumours.

Cambium Bio has cleared key regulatory hurdles for its lead dry eye disease treatment, Elate Ocular, and strengthened its balance sheet with a $2.12 million placement to support upcoming Phase 3 trials.

Hydralyte USA reported an 8.5% rise in Q2 FY25 net sales, driven by strong May performance and improved margins, while preparing to launch new brain and gut health products.

Prescient Therapeutics has raised nearly $10 million through a placement and share purchase plan to advance its promising PTX-100 targeted cancer therapy into pivotal clinical stages.

Medical Developments International (MVP) reports positive operating cash flow in H2 FY25, driven by strong Penthrox sales and strategic distribution shifts in Europe. The company eyes further growth amid regulatory progress and efficiency gains.

InteliCare Holdings reported a $564,000 operating cash outflow in Q4 2025 and has secured $1 million in additional funding to support ongoing operations despite a cash runway under one quarter.

Resonance Health reports a solid quarter with key clinical trial milestones, expansion of trial sites, and multi-year Software-as-a-Medical Device contracts, underpinning a positive cashflow outlook.

Hydrix Limited reports steady June quarter revenues with a 10% rise from the prior quarter, supported by new contract wins and a robust $40 million project pipeline.

Imugene Limited reports strong clinical progress with its off-the-shelf CAR T therapy azer-cel achieving a 75% overall response rate in Phase 1b trials, alongside new patents and leadership appointments. The company also secured $22.5 million in fresh funding to advance pivotal trials.

MedAdvisor Solutions reported a 16.6% revenue decline in 4Q FY25, driven by US market challenges, while completing the sale of its ANZ business and initiating a strategic review of its US operations.

EVE Health Group has completed its acquisition of Nextract, raised $1 million to fund manufacturing, and achieved key regulatory and commercial milestones for its pharmaceutical products targeting erectile dysfunction and dysmenorrhea.